Resource Summary Report

Generated by RRID on Sep 10, 2026

European Medicines Agency

RRID:SCR_011215
Type: Tool

Proper Citation

European Medicines Agency (RRID:SCR_011215)

Resource Information

URL: http://www.ema.europa.eu/

Proper Citation: European Medicines Agency (RRID:SCR_011215)

Description: An agency responsible for the evaluation and supervision of medicines developed by pharmaceutical companies for use in the European Union. Its main responsibility is the protection and promotion of public and animal health through the evaluation and supervision of medicines for human and veterinary use. The Agency also plays a role in stimulating innovation and research in the pharmaceutical sector. The Agency gives scientific advice and other assistance to companies for the development of new medicines. It publishes guidelines on quality-, safety- and efficacy-testing requirements. A dedicated SME Office provides special assistance to small and medium-sized enterprises.

Abbreviations: EMA

Synonyms: EU Medicines Agency

Resource Type: nonprofit organization

Resource Name: European Medicines Agency

Resource ID: SCR_011215

Alternate IDs: grid.452397.e, Wikidata: Q130146, nif-0000-30532

Alternate URLs: https://ror.org/01z0wsw92

Record Creation Time: 20220129T080303+0000

Record Last Update: 20260905T132657+0000

Ratings and Alerts

No rating or validation information has been found for European Medicines Agency.

No alerts have been found for European Medicines Agency.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 388 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Baron A, et al. (2026) The European medicines agency review of belzutifan (Welireg) for the treatment of adult patients with von Hippel-Lindau disease-associated tumors. The oncologist, 31(2).

Agostini V, et al. (2026) Pediatric Investigation Plans for seizure and epilepsy treatments: An analysis since the implementation of the European Pediatric Regulation in 2006. Epilepsia, 67(3), 1267.

Saadeldeen AM, et al. (2026) A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics. Frontiers in pharmacology, 17, 1834343.

Iglesias-Lopez C, et al. (2026) Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective. Therapeutic innovation & regulatory science, 60(3), 823.

Mortato E, et al. (2026) AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks. Dermatology and therapy, 16(4), 2191.

Meeta M, et al. (2026) Clinical Practice Guidelines for Menopause: An Executive Summary and Recommendations: Indian Menopause Society 2026. Journal of mid-life health, 17(Suppl 1), S12.

, et al. (2026) Knowledge mapping of risk mitigation measures against vector-borne diseases. EFSA journal. European Food Safety Authority, 24(5), e10060.

Singer J, et al. (2026) Retrospective Cohort Analysis of Treatment Patterns, Survival, and Cost-Effectiveness in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Lower Austria (2018-2022). Cancer medicine, 15(3), e71667.

Starek M, et al. (2026) Insights into dietary supplements as popular product supporting the diet. Naunyn-Schmiedeberg's archives of pharmacology, 399(6), 7711.

Auvin S, et al. (2026) Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE

Task Force on Regulatory Affairs. Epilepsia, 67(6), 2743.

Dadouch M, et al. (2026) Capillary Zone Electrophoresis for the Analysis of Phenolic Preservatives in Plasma and Insulin Formulations Using Salting-Out Assisted Liquid-Liquid Extraction. Electrophoresis, 47(4), 308.

Švajger U, et al. (2026) The Landscape of Advanced Therapy Medicinal Products in Slovenian Transfusion Medicine: A Review of Past and Future Outlook. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 53(3), 145.

?ab?d?-Mas?owska A, et al. (2025) Evaluation of the Safety and Regenerative Potential of Human Mesenchymal Stem Cells and Their Extracellular Vesicles in a Transgenic Pig Model of Cartilage-Bone Injury In Vivo - Preclinical Study. Stem cell reviews and reports, 21(4), 1075.

Lazzari E, et al. (2025) Investigation of Natural Resistance to Fostemsavir and Lenacapavir in Naïve Primary Infections by Ultra-Deep Sequencing of near Full-Length HIV-1 Genomes. Viruses, 17(5).

Panaitescu-Damian A, et al. (2025) Addressing Pancreatic Exocrine Insufficiency and the Impact of Pancreatic Enzyme Replacement Therapy Shortages in Europe. United European gastroenterology journal, 13(10), 2090.

da Cruz AF, et al. (2025) Melanoma treatment in the era of nanotechnology and precision medicine. Journal of nanobiotechnology, 24(1), 67.

Siebenhüner AR, et al. (2025) Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors. Endocrine-related cancer, 32(6).

Patrinos GP, et al. (2025) Systematic analysis of the pharmacogenomics landscape towards clinical implementation of precision therapeutics in Greece. Human genomics, 19(1), 11.

Giraudet R, et al. (2025) Immunogenicity of single-chain antibodies: germlining of a VHH lowers T-cell activation from epitopes in FR2 and CDR regions. mAbs, 17(1), 2571406.

De Brouchoven I, et al. (2025) Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome. Frontiers in pediatrics, 13, 1475143.